Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
CIK #0001604821
SectorLife Sciences
IndustryServices-Medical Laboratories
Address201 Industrial Road Suite 410
San Carlos, CA 94070
Source [EDGAR]
Market Cap, 13F ($MM)

We are a diagnostics company with proprietary molecular and bioinformatics technology that we are deploying to change the management of disease worldwide. Our novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Our statistical algorithms combine these measurements with data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with best-in-class accuracy and coverage. Our technology has been proven clinically and commercially in the reproductive health space, in which we develop and commercialize non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome. We are now translating our success in reproductive health and applying our core technology to the oncology market, in which we are commercializing a blood-based DNA test to detect residual disease and monitor disease progression and treatment response, as well as to the organ transplant market, with a test to assess kidney transplants for rejection. We seek to enable even wider adoption of our technology through our global cloud-based distribution model. In addition to our direct sales force in the United States, we have a global network of over 100 laboratory and distribution partners, including many of the largest international laboratories.

Since 2009, we have launched a comprehensive suite of ten products in reproductive health, as well as our personalized molecular monitoring test for use in oncology and our transplant rejection test. We intend to continue to launch new products in the future.

We launched Panorama, our non-invasive prenatal test, or NIPT, in March 2013 and have since gone from being the fourth company to enter the NIPT market to being the market leader by volume in the United States. We launched our Horizon carrier screening test in 2012. Panorama and Horizon together represent the significant majority of our revenues. Our revenues were $302.3 million in 2019 compared to $257.7 million in 2018 and $209.6 million in 2017, as revised under Accounting Standards Codification Topic 606, or ASC 606. Our revenues are primarily generated from testing in reproductive health, and were $269.9 million, $240.4 million and $203.8 million for the years ended December 31, 2019, 2018 and 2017, respectively. Our net losses decreased to $124.8 million in 2019 from $128.2 million in 2018, which in turn decreased from $137.6 million in 2017.

CIK Filing 2011 - 2021
[0001604821] 10-K
[0001604821] 10-Q
[0001604821] 3
[0001604821] 4
[0001604821] 5
[0001604821] 8-K
[0001604821] SC 13D
[0001604821] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Capital World Investors Natera Inc [2020-02-14] 6.1
BlackRock Inc Natera Inc [2020-02-07] 6.4
Integrated Core Strategies US LLC Natera Inc [2019-04-23] 4.0
FMR LLC Natera Inc [2019-02-13] 0.0
Jennison Associates LLC Natera Inc [2019-02-01] 6.0
Prudential Financial Inc Natera Inc [2019-01-28] 6.1
Vanguard Group Inc Natera Inc [2018-02-09] 5.04
Flynn James E Natera Inc [2017-12-11] 5.17
Lightspeed Venture Partners VIII LP Natera Inc [2017-02-14] 0.0
Lightspeed Venture Partners VIII LP Natera Inc [2016-02-16] 7.9
Capital World Investors Natera Inc [2016-02-12] 5.7
Rabinowitz Matthew Natera Inc [2016-02-12] 10.0
Sequoia Capital XII A Delaware L P Natera Inc [2016-02-12] 13.5
Claremont Creek Ventures L P Natera Inc [2016-02-10] 14.8
Sofinnova Venture Partners VIII LP Natera Inc [2015-07-13] 11.0
Form 3/4/5 Filer 2011-2021
Chapman Steven Leonard
Brophy Michael Burkes
Sheena Jonathan
Schueren Robert Alan
Rabinowitz Matthew
Bertagnolli Monica
Botha Roelof
Marcus Gail Boxer
Chapman Rowan E
Baynes Roy D
Rosenman Herm
Healy James
Cozzens Todd C
Driscoll Edward C Jr
Steuart John
SC XII Management LLC
Sequoia Technology Partners XII A Delaware L P
Sequoia Capital XII Principals Fund LLC
Sequoia Capital XII A Delaware L P
Claremont Creek Ventures L P
Claremont Creek Partners Fund L P
Claremont Creek Partners II LLC
Claremont Creek Ventures II LP
Claremont Creek Partners LLC
Goldhaber Nathaniel
Hawks Randall
Schaepe Christopher J
NIEH Peter
Mhatre Ravi
Lightspeed Ultimate General Partner VIII Ltd
Lightspeed General Partner VIII LP
Lightspeed Venture Partners VIII LP
Eggers Barry
MM Shares Owned of 61.8 MM Total
Firm Period DFND Voting Shares
Vanguard Group Inc [2020-09-30] SOLE 0.0 6.9
Fred Alger Management Inc [2020-09-30] SOLE 5.3 5.6
BlackRock Inc. [2020-09-30] SOLE 5.3 5.5
Wells Fargo & Co/Mn [2020-09-30] DFND 0.6 3.3
Sofinnova Investments Inc [2020-09-30] SOLE 3.1 3.1
JPMorgan Chase & Co [2020-09-30] DFND 2.6 3.1
State Street Corp [2020-09-30] DFND 1.9 2.2
OrbiMed Advisors LLC [2020-09-30] DFND 0.3 2.1
Jennison Associates LLC [2020-09-30] DFND 2.0 2.0
Macquarie Group Ltd [2020-09-30] SOLE 1.9 1.9
FMR LLC [2020-09-30] DFND 0.3 1.8
Ameriprise Financial Inc [2020-09-30] DFND 0.0 1.8
RTW Investments LP [2020-09-30] SOLE 1.7 1.7
Capital World Investors [2020-09-30] DFND 1.4 1.4
Invesco Ltd. [2020-09-30] DFND 0.0 1.4
Millennium Management LLC [2020-09-30] SOLE 1.3 1.3
Gilder Gagnon Howe & Co LLC [2020-09-30] DFND 0.0 1.3
Bridger Management LLC [2020-09-30] SOLE 1.3 1.3
Point72 Asset Management LP [2020-09-30] DFND 0.0 1.3
Credit Suisse AG [2020-09-30] DFND 1.2 1.2
Geode Capital Management LLC [2020-09-30] DFND 1.1 1.1
Federated Investors Inc /PA/ [2020-09-30] DFND 1.1 1.1
Lord Abbett & Co LLC [2020-09-30] SOLE 0.9 1.0
Goldman Sachs Group Inc [2020-09-30] DFND 0.9 0.9
Northern Trust Corp [2020-09-30] DFND 0.2 0.9
Janus Henderson Group PLC [2020-09-30] DFND 0.0 0.9
Hood River Capital Management LLC [2020-09-30] SOLE 0.7 0.8
Driehaus Capital Management LLC [2020-09-30] SOLE 0.6 0.8
Nuveen Asset Management LLC [2020-09-30] DFND 0.8 0.8
Kornitzer Capital Management Inc /KS [2020-09-30] SOLE 0.7 0.7
Prev | Page 1 | Next
Terms | Privacy | Guide